These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21910704)

  • 1. Cutaneous pseudolymphoma induced by adalimumab and reproduced by infliximab in a patient with arthropathic psoriasis.
    Imafuku S; Ito K; Nakayama J
    Br J Dermatol; 2012 Mar; 166(3):675-8. PubMed ID: 21910704
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cutaneous pseudolymphoma with two types of anti-TNFα: a class effect?].
    Schmutz JL; Trechot P
    Ann Dermatol Venereol; 2012 Oct; 139(10):695-6. PubMed ID: 23122389
    [No Abstract]   [Full Text] [Related]  

  • 3. Cutaneous pseudolymphoma caused by tumor necrosis factor-α inhibitors was not induced by ustekinumab.
    Imafuku S; Tatsukawa R; Ito K; Nakayama J
    J Dermatol; 2012 Dec; 39(12):1070. PubMed ID: 22698067
    [No Abstract]   [Full Text] [Related]  

  • 4. [Infliximab].
    Herrera E; Habicheyn S
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():7-13. PubMed ID: 19080986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab.
    Chew AL; Bennett A; Smith CH; Barker J; Kirkham B
    Br J Dermatol; 2004 Aug; 151(2):492-6. PubMed ID: 15327561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases.
    de Souza A; Ali-Shaw T; Reddy SM; Fiorentino D; Strober BE
    Br J Dermatol; 2013 Jan; 168(1):210-2. PubMed ID: 23278559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials.
    Mease PJ; Signorovitch J; Yu AP; Wu EQ; Gupta SR; Bao Y; Mulani PM
    Dermatology; 2010; 220(1):1-7. PubMed ID: 19940437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generalized pustular psoriasis-like eruptions induced after the first use of adalimumab in the treatment of psoriatic arthritis.
    Kimura U; Kinoshita A; Haruna K; Mizuno Y; Sekigawa I; Takamori K; Suga Y
    J Dermatol; 2012 Mar; 39(3):286-7. PubMed ID: 21957978
    [No Abstract]   [Full Text] [Related]  

  • 9. [Body-weight changes in psoriatic patients on systemic treatment].
    Forien M; Mahé E; Sin C; Marchal A; Sigal ML
    Ann Dermatol Venereol; 2012 Oct; 139(10):649-51. PubMed ID: 23122380
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.
    Girolomoni G; Altomare G; Ayala F; Berardesca E; Calzavara-Pinton P; Chimenti S; Peserico A; Puglisi Guerra A; Vena GA
    Immunopharmacol Immunotoxicol; 2012 Aug; 34(4):548-60. PubMed ID: 22296031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
    Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
    Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Onset of palmoplantar pustular psoriasis while on adalimumab for psoriatic arthritis: a 'class effect' of TNF-alpha antagonists or simply an anti-psoriatic treatment adverse reaction?
    Rallis E; Korfitis C; Stavropoulou E; Papaconstantis M
    J Dermatolog Treat; 2010 Jan; 21(1):3-5. PubMed ID: 19701844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review.
    Kamili QU; Miner A; Hapa A; Menter A
    J Drugs Dermatol; 2011 May; 10(5):539-44. PubMed ID: 21533302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertriglyceridaemia during treatment with adalimumab in psoriatic arthritis.
    Stinco G; Piccirillo F; Patrone P
    Br J Dermatol; 2007 Dec; 157(6):1273-4. PubMed ID: 17916219
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
    Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
    Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Injection Site Reactions to Biologic Agents Used in Psoriasis and Psoriatic Arthritis.
    Henderson Berg MH; Carrasco D
    J Drugs Dermatol; 2017 Jul; 16(7):695-698. PubMed ID: 28697222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alopecia areata universalis elicited during treatment with adalimumab.
    Pelivani N; Hassan AS; Braathen LR; Hunger RE; Yawalkar N
    Dermatology; 2008; 216(4):320-3. PubMed ID: 18230980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
    J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of bullous pemphigoid during treatment of psoriasis with adalimumab.
    Stausbøl-Grøn B; Deleuran M; Sommer Hansen E; Kragballe K
    Clin Exp Dermatol; 2009 Oct; 34(7):e285-6. PubMed ID: 19438555
    [No Abstract]   [Full Text] [Related]  

  • 20. No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: A report from 16 clinical studies of patients with psoriasis or psoriatic arthritis.
    Mrowietz U; Riedl E; Winkler S; Xu W; Patel H; Agada N; Lebwohl MG
    J Am Acad Dermatol; 2020 Nov; 83(5):1436-1439. PubMed ID: 32526319
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.